News Archive

August 2020

• Press Release Aug 26, 2020

  Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study

  At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with…
• In The News Aug 26, 2020

  The coronavirus is giving health and pharma companies a chance to woo tech talent

  Novartis Chief Digital Officer Bertrand Bodson says tech professionals don’t need a background in biology to switch industries.
• Press Release Aug 22, 2020

  Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma

  Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported…
• 
  Story Aug 21, 2020 Discovery

  Building collaborations to fight a pandemic

  Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.

• Key Release Aug 20, 2020

  FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

  Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple…
• Key Release Aug 17, 2020

  Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent

  Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our…
• 
  Featured News Aug 12, 2020

  Novartis appoints Marc Boutin as Global Head of Patient Engagement & Advocacy

• 
  Story Aug 06, 2020 Access to Healthcare

  Ensuring medicine supply to patients during COVID-19

  Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.

• Press Release Aug 06, 2020

  Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

  EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1 Chronic…
• Press Release Aug 05, 2020

  Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

  Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1…
• Press Release Aug 04, 2020

  Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

  Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously…
• Press Release Aug 03, 2020

  Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis

  EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …